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Abstract
Cancer risk depends on a combination of our genes, environment and other aspects of our 
lives, many of which we can control. Surgery, radiation and chemotherapy are often effective 
at treating people with a solid tumor, but once the cancer has spread and formed tiny tumors 
at distant sites, chances for a successful recovery are dismal.Recently, it was discovered that 
the malaria parasite, Plasmodium falciparum produce and present a malarial protein called 
VAR2CSA, which bind a type of sugar molecule exclusively found in the placenta. It was found 
that the exact same sugar molecule structure is also found in most cancer cells. Both molecules 
are a type of chondroitin sulfate. The VAR2CSA only adhere in the placenta and do not bind to 
chondroitin sulfate expressed elsewhere in the body. In tumors, placental-like chondroitin sulfate 
chains are linked to a limited repertoire of cancer-associated proteoglycans including CD44 
and CSPG4. The recombinant VAR2CSA (rVAR2) protein localizes to tumors in vivo and rVAR2 
fused to diphtheria toxin or conjugated to hemiasterlin compounds strongly inhibits in vivo tumor 
cell growth and metastasis. 
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Introduction
Cancer remains a major public health 
problem, it has a complex pathophysiology. 
Cancer is an effective family of more than 100 
unique conditions and is collectively characterized 
by the presence of cell populations that undergo 
uncontrolled division that displays the potential to 
invade other tissues. In 2014, more than13 million 
new cancer cases worldwide were recorded; 
70% of all cancer deaths occurred in low-to-
middle income countries (Soper & Rasooly, 2016).
Cancer will not be recovered until it is 
understood and knowing the unique alterations 
that identify normal cells from tumor cells (Berger 
et al., 2015). The optimum ideal strategy has 
not yet been announced. Each one has its own 
advantages and disadvantages even though a 
number of them have found their way for clinical 
application. The combination of strategies can 
be used to improve the precision of drug delivery, 
leading to a more effective personalized therapy 
(Bazak et al., 2015).
Greaves (2014) has a frustrated opinion 
which may reflect the reality, he believes that 
most cancers cannot be recuperated and 
scientists must look for other ways to treat the 
disease, as developing more advanced cures 
would lead to cancer cells becoming more 
resistant to treatment. He added that scientists 
should focus on prevention, such as aspirin which 
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stop the onset of stomach cancer, and respite 
the disease once it has emerged.
The deadly disease offers the means 
to another cure, and from this point, a team 
of researchers accidentally discovered a new 
protein called malaria protein, Variant Surface 
antigen 2-CSA (VAR2CSA), produced by the 
mosquito-borne parasite. VAR2CSA binds to a 
particular type of sugar molecule present in the 
placenta, which is also found on the majority of 
cancer cell types. It was found that, by attaching 
toxins to VAR2CSA, over 90 per cent of tumor cell 
lines were effectively cured across a broad array 
of cancer types such as brain, blood, gastric, 
lung, skin, prostate, ovarian, pancreatic, bladder, 
and breast cancers (Salanti et al., 2015). 
This article shed light on the role of 
malaria protein in fighting cancer cells as per the 
latest research finding.
Cancer
Cancer cells have a unique physiology.
Human body is made up of more than a 
hundred million million (100,000,000,000,000) cells. 
In usual, human body has just the right number of 
each type of cell. Normal cells produce signals 
to control how much and how often the cells 
divide. If any of these signals are faulty or missing, 
cells may start to grow and multiply too much 
and form a lump called a tumor (Figure 1). Where 
the cancer starts is called the primary tumor 
(Murekatete, 2015). When   the cancer cells 
leave a primary tumor and form one or several 
secondary tumors in other parts of the body; 
these secondary tumors are called metastatic 
tumors or metastases (Vanharanta & Massague, 
2013). Cancer occurs as a result of accumulating 
genetic and epigenetic alterations in self-
renewing cells that lead to unrestrained cell 
proliferation, resistance to apoptosis, immune 
evasion and tumor spread (He & Sharpless, 2016). 
Some tissues give rise to cancer in 
humans a million times more frequently than 
others.  Tomasetti & Vogelstein (2015) conclude 
that these differences can be explained by 
the number of stem cell divisions. They found a 
strong correlation extending over five orders of 
magnitude when they plotted the incidence of 
various cancers against the estimated number 
of normal stem cell divisions in the corresponding 
tissues over a lifetime.  Tomasetti & Vogelstein 
(2015) suggested that random errors occurring 
during DNA replication in normal stem cells are a 
Figure 1. Stages of cancer cell formation. Normal cells (orange), often after long-term exposure to carcinogens, can obtain changes 
in key molecular pathways and cause uncontrolled proliferation (light purple) leading to a premalignant or precancerous lesion. 
After accumulating additional alterations, cells are able to invade surrounding tissues forming a tumor (dark purple), in some cases, 
precancerous lesions naturally regress as marked by the bidirectional arrows. Functional immune cells (blue) with the capability of 
recognizing and destroying abnormal cells may eventually be repressed (black) by activation of immune checkpoints (Campbell 
et al., 2016).
major contributing factor in cancer development. 
Remarkably, this “bad luck” component explains 
a far greater number of cancers than do 
hereditary and environmental. This notion was 
supported by Weinberg & Zaykin (2015) who 
mentioned that  the importance of errors in DNA 
replication, has been viewed as implying that 
most cancers arise through bad luck, leading 
to the suggestion that research efforts should 
focus on early detection, rather than etiology or 
prevention factors (Figure 2). It was found that 
the major types and most abundant cancers in 
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a given population will originate from tissues that 
have relatively high stem cell division rates and 
that have a high prevalence of strong relevant 
risk factors (Giovannucci, 2016).
Figure 2. Cancers caused by bad luck and cancer caused by environment, genes and life style. [http://www.telegraph.co.uk/
news/science/science-news/11320497/ (2015)]
The majority of cancer survivors have 
been treated with aggressive medical, radiation 
and surgical therapies administered either at a 
time when a patient's organs were still developing, 
leading to complications later in life, or when the 
patient was already suffering from underlying 
degenerative processes where the side effects 
of therapy represent harm over injury (Valdivieso 
et al., 2012). Since1990s, oncologists focused 
on eliminating all fast-replicating cells, normal 
or cancerous, by radiation or chemotherapy 
(Berger el al., 2015). 
It was reported that the major 
challenges in cancer treatment is development 
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of agents that can be used for early diagnosis 
and effective therapy. Classical cancer 
management frequently lacks accurate tools for 
early tumors detection and has an associated risk 
of serious adverse effects of chemotherapeutics. 
Therefore, the need to optimize therapeutic ratio 
and have a treatment that recognize and affect 
cancer cells only (Bazak et al., 2015).
Malaria
Malaria is one of the world's leading 
causes of morbidity and mortality with an 
estimated 438 000 malaria deaths and 214 million 
new cases of malaria worldwide. Malaria is 
caused by Plasmodium parasites. The parasites 
are spread to people through the bites of 
infected female Anopheles mosquitoes, called 
"malaria vectors”.  The mosquito bite introduces 
the parasites from the mosquito's saliva into a 
person's blood (World Health Organization, 2015). 
After that, the parasites migrate to the liver and 
infect the hepatocytes. Over 7–10 days, the 
parasites develop and divide into merozoites 
that are released into the blood stream. During 
the blood-stage of infection with Plasmodium , 
the merozoite invades red blood cells (RBCs; 
reticulocytes and mature erythrocytes) and 
replicates inside them (Beeson et al., 2016) 
(Figure3).
According to World Health Organization 
(2015), there are five parasite species that cause 
malaria in humans, and two of which Plasmodium 
falciparum (P. falciparum) and Plasmodium 
vivax (P. vivax) – confuse  the greatest threat.   P. 
falciparum is the most prevalent malaria parasite 
on the African continent. It is responsible for 
most malaria-related deaths globally, and P. 
vivax has a wider distribution than P. falciparum, 
and predominates in many countries outside of 
Africa.
Figure 3. Life cycle of the malaria parasite. [http://rstb.royalsocietypublishing.org/content/366/1579/2806 (2011)]
Malaria was found to affect young 
children and pregnant women. During 
pregnancy, malaria is associated with placental 
infection, maternal anemia, low birth weight 
infants, and increased neonatal morbidity and 
mortality (Gnidehou et al., 2014). 
For most of its human life cycle, the 
parasite stays within the liver and blood cells and is 
relatively invisible to immune surveillance. It avoid 
destroyed in the spleen by adhesive proteins on 
the surface of the infected blood cells, causing 
the blood cells to stick to the walls of small 
blood vessels, thereby insulate the parasite from 
passage through the general circulation and 
185
Fadl & Mannaa (2017) / Can malaria protein ...
Com. Sci., Bom Jesus, v.8, n.2, p.181-193, Abr./Jun. 2017
the spleen (Tilley et al., 2011). The blockage of 
the microvasculature causes symptoms such 
as in placental malaria (Mens et al., 2010) and 
when the sequestered red blood cells breach 
the blood–brain barrier  cause cerebral malaria 
(Rénia et al., 2012). 
Plasmodium falciparum
Plasmodium falciparum causes the most 
virulent form of malaria (Liet al., 2006; WHO, 
2015). When the parasites invade erythrocyte, 
several modifications are induced in the 
infected erythrocyte, especially on its surface 
membrane. One of the important modifications 
is the formation of nanoscale protrusions, which 
are known as knobs (Shi et al., 2013). Knobs 
are 50 to 120 nm in diameter and 2 to 20 nm in 
height (Quadt et al., 2012) and act as a site for 
anchoring P. falciparum erythrocyte membrane 
protein 1 (PfEMP1) (Smith et al., 2013) (Figure 
4). PfEMP1 is a highly polymorphic family of 
proteins with about 60 members, encoded by 
the var gene ensemble, that are transported to 
the surface of parasitized erythrocytes, with their 
extracellular region exposed for interaction with 
diverse host receptors (Bentley & Gamain,  2008).
The role of PfEMP1 is to enable adhesion 
of infected erythrocyte to various host receptors 
to avoid splenic clearance, and clonal 
antigenic variation allows infected erythrocyte 
to evade immune recognition. For this reason 
Plasmodium falciparum malaria is more severe 
than disease caused by other malaria species 
(Subramani et al., 2015). In this concern, Salanti 
and his team (2015) observed that P. falciparum-
infected erythrocytes cannot bind anywhere in 
vascularized tissue compartments, except in the 
placenta.
Figure 4. Plasmodium falciparum infected red blood cells. [http://biology.anu.edu.au/research/projects/erythrocyte-
membrane-modifications-during-malaria-infection (2015)]
VAR2CSA
VAR2CSA, a member of the PfEMP1 
variant surface antigen family. VAR2CSA is a large 
protein (350 kDa) that is structurally composed 
of six Duffy binding-like (DBL) domains (DBL1X, 
DBL2X, DBL3X, DBL4ε, DBL5ε, and DBL6ε) among 
them, three mediate binding to chondroitin 
sulfate A (CSA) (Clausen et al., 2012) (Figure 5).
VAR2CSA has extracellular, 
transmembrane, and intracytoplasmic regions, 
and its extracellular region is uniquely structured 
among PfEMP1 family members. The extracellular 
region of VAR2CSA which includes an N-terminal 
sequence, 6 cysteine-rich Duffy binding like 
(DBL) domains, and inter-domain (ID) regions, 
increasingly appear to play a key role in adhesion 
and immunogenicity of recombinant VAR2CSA 
protein fragments (Fried &  Duffy, 2015) (Figure 5).
  PfEMP1 proteins including VAR2CSA are 
encoded in the genome of P. falciparum but not 
that of other human malaria parasites (Fried & 
Duffy, 2015). VAR2CSA expressing parasites only 
adhere in the placental chondroitin sulfate (CS) 
and do not bind to CS expressed elsewhere in the 
body (Salanti et al., 2004; 2015).
Chondroitin Sulfate (CS)
Chondroitin sulfate (CS) is a 
glycosaminoglycan (GAG) composed of 
repeating disaccharides of glucuronic acid and 
N‐acetyl‐galactosamine, which are variously 
substituted by sulfate groups. It is covalently 
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attached on several core proteins creating 
a variety of proteoglycans (PGs) found in the 
extracellular matrix (ECM) and cell membrane, 
but also intracellularly (Elgawish et al., 2015). 
Chondroitin sulfate interacts with a wide variety of 
key molecules, such as growth factors, cytokines, 
chemokines, adhesion molecules and lipoproteins 
via specific saccharide domains within the chain. 
These interactions regulate many important 
physiological processes and cell behavior. 
Several diseases are often associated with a 
biosynthetic imbalance of chondroitin sulfate 
proteoglycans (CSPGs). CSPGs are markedly 
increased in early atherosclerotic lesions, playing 
important roles in lipid retention, modification, 
and finally accumulation. In addition, CSPGs 
participate in inflammatory process associated 
with atherosclerosis and influence arterial smooth 
muscle cell behavior. They also directly affect 
elastogenesis and proper formation of the 
extracellular matrix (Theocharis et al., 2006; Poh 
et al., 2015). 
In Pregnancy-associated malaria, 
an extensive accumulation of parasitized 
erythrocytes in the placental intervillous blood 
spaces mediated by adhesion to the placental 
chondroitin-4-sulfate (CSA) and has been linked 
to the severe disease outcome (Bentley & 
Gamain, 2008).
Plasmodium falciparum-infected red 
blood cells (IRBCs) bound to chondroitin sulfate 
A (CSA) (Figure 6) but not to other extracellular 
matrix proteins or to other known IRBC receptors. 
IRBCs from non-pregnant donors did not bind 
to CSA (Fried and Duffy, 1996) .This in parallel 
with Salanti et al (2003) who reported that  CSA-
adhering parasites are rarely found in non-
pregnant hosts, placental parasites preferentially 
or perhaps even exclusively bind to CSA.
The placental CS, although incompletely 
resolved, is a distinct CS subtype expressed 
exclusively in the placenta. The function of 
placental-like CS (pl-CS) chains is not fully 
understood, but they are associated with the 
ability of trophoblasts to invade the uterine tissue 
and promote rapid cell proliferation as part of the 
Figure 5. A schematic representation of the VAR2CSA PfEMP1 variant anchored to the membrane of the infected erythrocyte. 
The DBL3x domain, illustrated as an enlargement in ribbon form. The subdomains 1, 2 and 3 are colored yellow, red and green, 
respectively. VAR2CSA binds to the CSA moiety of placental chondroitin sulfate proteoglycan present on the surface of the 
syncytiotrophoblast cells in the placenta. The CSA ligand is shown schematically as hexagons (blue), positioned over the region 
covering subdomains 2&3 (Bentley & Gamain, 2008).
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normal placental implantation process (Baston-
Bust et al., 2010). As proliferation and invasion 
are features shared with tumor cells, Salanti et al 
(2015) hypothesized that placenta and cancer 
might express a similar type of CS.
Notably that the chondroitin sulfate 
proteoglycans (CSPGs) such as versican 
accumulate in tumor stroma and play a key role 
in tumor growth and invasion. The high expression 
of CSPGs in fast growing tissues and cells is 
correlated with chondroitin sulfate (CS) chains 
and the sulfation pattern (Asimakopoulou et al., 
2008). The abundance of CSA increased with the 
advanced stage of the tumor (Ferrarelli, 2015).          
Poh et al (2015) mentioned in his article 
that GAGs have gained interest as potential 
therapeutic agents in cancer treatment, with 
studies showing their involvement in various 
pathobiological cancer stages.  An over 
expression of chondroitin sulfate (CS) has been 
identified in various cancer phenotypes such 
as prostate, testicular, gastric, pancreatic and 
breast cancer. For instance, compositional 
analysis of GAG side chains isolated from 
malignant breast tissues indicate an elevation 
in CS expression, with an increase in CS-A and 
CS-E sulfation sequences and a decrease in 
CS-C and CS-D. These indicate that the sulfate 
groups present on CS might play an important 
role in the cellular processes involved in the 
progression of breast cancer. This notion was 
supported by Guo et al   (2015) who mentioned 
that  the percentages of 4-sulfated chondroitin 
sulfate disaccharide and hyaluronic acid 
disaccharide in the sera of patients with cirrhosis 
and hepatocellular carcinoma were significantly 
increased, compared with healthy individuals. 
Similarly, Oliveira-Ferrer  et al (2015) added that 
the glycosaminoglycans are abundantly present 
in ovarian tumors, and there is rising evidence 
that chondroitin sulfate (CS) as well as diverse 
carbohydrate sulfotransferases (CHSTs), the 
enzymes involved in the sulfation process of these 
structures, plays an important role in metastatic 
spread of tumor cells.
Figure 6. Schematic representation of the to blood capillaries in the human placenta. A variant of PfEMP1 encoded by 
the var2CSA gene, expressed on the surface of infected erythrocytes, binds to CSA, a component of the proteoglycan matrix on 
placenta (Chishti, 2015).
Pregnancy associated malaria (PAM)
Pregnancy-associated malaria (PAM) 
has severe consequences for both mother and 
child. PAM is caused by P. falciparum–infected 
red blood cells that bind to receptors in the 
placenta. By adhesion to the placental tissue 
(sequestration), the parasites avoid being filtered 
though the spleen where they would have 
been killed (Andersen et al., 2008). This causes 
accumulation of infected red blood cells, leading 
to placental inflammation and block of blood 
flow to the developing fetus. This is associated 
with maternal anemia, low birth weight, and 
premature delivery and can lead to the death of 
mother and child (Higgins. 2008).
The IEs are however not passed from 
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the mother to the fetus, even in cases of 
heavy infection in which more than 50% of the 
erythrocytes are parasitized. They accumulate on 
the maternal side of the placenta, in the vascular 
spaces between the villi where nutrient and gas 
exchange occurs (Wahlgren & Spillmann., 2000).
The mechanism by which P. falciparum-
infected erythrocytes (IEs) sequester in the 
placenta is mediated by an interactions between 
P. falciparum erythrocyte membrane protein 
1 (PfEMP1) domains (variant protein named 
VAR2CSA) and chondroitin sulfate A (CSA) on 
the syncytiotrophoblasts (Figure 6) of placenta 
(Andersen et al., 2008; Gnidehou et al., 2014). 
Is there a relation between infection with malaria 
and incidence of cancer?
In 2010, Lehrer reported that there was 
a significant association between malaria and 
cancer mortality in 50 US states. The association 
can be possibly explained by the well established 
ability of Plasmodium to induce suppression of 
the immune system. A second explanation may 
be that the Anopheles mosquito, the vector of 
malaria, transmits an obscure virus that initially 
causes only a mild transitory illness but much later 
predisposes to cancer. 
On the other hand, Chen et al (2011) 
reported that Malaria infection significantly 
suppresses Lewis lung cancer growth in a mouse 
model by inducing both a potent anti-tumor 
innate immune response, including the secretion 
of IFN-γ and TNF-α and the activation of natural 
killer cells as well as adaptive anti-tumor immunity 
with increasing tumor-specific T-cell proliferation 
and cytolytic activity of T cells.  He suggested 
that the malaria parasite may provide a novel 
strategy or therapeutic vaccine vector for anti-
lung cancer immune-based therapy.
Recently, Robbiani et al (2015) decided 
to find out the link between the parasite that 
causes malaria, infects red blood cells and liver 
cells, and increase a child’s risk of developing of 
one of the most frequent cancers among African 
children called Burkitt’s lymphoma. Robbiani 
et al (2015) studied malaria infections in mice 
and  discovered that during prolonged immune 
responses to malaria, B lymphocytes multiply 
extensively and show prolonged expression 
of an enzyme called AID (activation-induced 
cytidine deaminase). Normally, AID mutates 
DNA at antibody genes to promote shuffling of 
DNA, which generates the diversity of antibodies 
so crucial for combating infections. However, 
Robbiani's team found that in malaria-infected 
B lymphocytes; AID instead revenge widespread 
devastation, causing DNA rearrangements at 
other genes, including those involved in the 
development of cancer.
Treatment of cancer with malaria protein
In the recent decades, scientists 
have been searching for similarities between 
the growth of a placenta and a malignant 
compartment (Holtan et al., 2009). The placenta 
is a fast-growing organ in which cells display high 
mitotic rates and within a few months grows 
from only few cells into an organ weighing 
approximately two pounds and it provides 
the embryo with oxygen and nourishment in a 
relatively foreign environment. Placenta also has 
the ability to maintain high proliferation rates and 
the capacity of the villous trophoblasts to invade 
into uterine tissue during implantation (Baston-
Bust et al., 2010; Van Sinderen et al., 2013), these 
are features shared with tumors, and they grow 
aggressively in a relatively foreign environment 
(Salanti et al., 2015).
Now as per the latest research findings, 
when researchers (Salanti et al., 2015) were trying 
to develop an anti-malaria vaccine in pregnant 
women they discovered an unexpected side 
benefit that could potentially transform cancer 
therapy. They revealed that the carbohydrate 
that the malaria parasite attaches itself  to – an 
oncofetal chondroitin sulfate (CSA) – which is 
expressed in the placenta is the same as the one 
displayed on proteoglycans in cancerous cells 
(the placental and malignant compartments 
display a common CS signature that binds 
malarial protein,VAR2CSA,) (Figure  7).
Salanti and his colleagues (2015) 
suggested that the sugar molecule (CSA) could 
be a target for anti-cancer drugs, and that the 
VAR2CSA malarial protein could provide the 
tool for delivering cancer killing toxins to tumors 
(attach a poison-carrying protein from the 
malaria parasite directly onto the cancer cell, 
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thereby killing the cancer).
To examine this idea, the researchers 
(Salanti et al., 2015) separated the malaria 
protein (VAR2CSA), which attaches itself to the 
carbohydrate (CSA) and chemically conjugated 
it to a diphtheria toxin (rVAR2), (Figure 7) then 
tested in vitro on a thousands of samples from 
brain tumors to leukemia's, the general picture 
emerges to indicate that the malaria protein 
is able to attack more than 90% of all types of 
tumors. Researchers took their drug one step 
further and tested it out on mice that were 
implanted with three different human cancers. 
With non-Hodgkin's lymphoma, the treated 
mice's tumors were about a quarter the size of 
the tumors in the control group. With prostate 
cancer, the tumors disappeared in two of the 
six treated mice a month after receiving the first 
dose. With metastatic bone cancer, five out of 
six of the treated mice were alive after almost 
eight weeks, compared to none of the mice in a 
control group (Figures 8 e 9). 
Figure 7. The malarial protein VAR2CSA binds a placenta-specific chondroitin sulfate (CS). Same CS is present in high fractions of 
cancer cells of many cancer types and that recombinant VAR2CSA conjugated with therapeutics strongly inhibit in vivo tumor 
growth (Salanti et al., 2015).
Figure 8. Malaria protein (green) binding to cancer cells.
http://www.zmescience.com/medicine/malaria-cancer-trials-20102015/ (2015)
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Histopathological examination of 
different organs did not show any evidence 
of adverse cytotoxic effects. These data 
demonstrate that rVAR2 can facilitate efficacious 
CS dependent delivery of a cytotoxic compound 
to tumors in vivo, rVAR2 were able to inhibit tumor 
growth and metastasis with no orphologic 
evidence of adverse effects on normal tissues 
(Bernstein, 2015; Salanti et al., 2015). 
Obviously, this treatment cannot be 
applied to pregnant women. Since the rVAR2-
conjugated toxin cannot distinguish placenta 
from tumor, it would inhibit placenta growth as 
well (Salanti et al., 2015).
According to the opinion of  Salanti and 
his team (2015),  he concluded that his study 
offered compelling evidence that diverse human 
and murine tumor types can be effectively 
targeted in vivo using an rVAR2 drug conjugate, 
and this is supported by the observation that P. 
falciparum-infected erythrocytes cannot bind 
anywhere in vascularized tissue  compartments, 
except in the placenta.
On the other hand, Lassen (2015), 
although he is exciting with mechanism involved 
in using rVAR2 drug, and the results of animal tests, 
but he emphasized that the cancer treatment 
will not necessarily work in human, as , it is easier 
to treat mice than people and unforeseen side 
effects may yet emerge when tested on cancer 
patients.
Figure 9. Malaria proteins with toxins attached appeared to target cancer cells, and not healthy ones, during 
experiments with mice. http://www.upi.com/Health_News/2015/10/14/Malaria-vaccine-research-may-lead-to-
cure-for-cancer/5851444835216/ (2015)
Conclusion
Cancer risk factors include exposure to 
chemicals or other substances, as well as certain 
behaviors. They also include things people 
cannot control, like age and family history. A 
family history of certain cancers can be a sign of 
a possible inherited cancer syndrome.
Surgery, radiation and chemotherapy 
are often effective at treating people with a 
solid tumor but once the cancer has spread 
(metastases) and formed tiny tumors at distant 
sites, chances for a successful recovery are 
dismal and it represented 90 percent of people 
who die from cancer.
Group of  Danish scientists from the 
University of Copenhagen and the University 
of  British Columbia, while trying to develop an 
anti-malaria vaccine in pregnant women, they 
discovered that the malaria parasite, Plasmodium 
falciparum produce and present a malarial 
protein called VAR2CSA, which binds a distinct 
type sugar called chondroitin sulfate (CS) 
exclusively expressed in the placenta. The same 
CS modification is present on a high proportion 
of cancer cells and that it can be specifically 
targeted by recombinant VAR2CSA (rVAR2). 
In tumors, placental-like CS chains are linked 
to a limited repertoire of cancer-associated 
proteoglycans including CD44 and CSPG4. The 
rVAR2 protein localizes to tumors in vivo and 
rVAR2 fused to diphtheria toxin or conjugated to 
hemiasterlin compounds strongly inhibits in vivo 
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tumor cell growth and metastasis. 
Out of the idea "take a small component 
of a fetal disease and then used it to target 
another disease", By using the same mechanism 
of binding of the malaria protein (VAR2CSA) to 
the sugar molecule (CSA), they tested a drug 
that combines the malaria protein with an 
anticancer toxin, first in cell lines and then in mice. 
In cell lines, they found that the combination 
drug specifically targeted and killed more than 
90% of cancer cell lines. And in mice implanted 
with three types of human tumors - the drug also 
showed varying degrees of success. In mice with 
non-Hodgkin's lymphoma, the treated tumors 
shrank to a quarter of the size of untreated tumors. 
Treated mice within a month of administering the 
first dose, and with metastatic breast cancer, five 
of six treated mice were cured of the disease. 
In all groups the mice showed no adverse side 
effects from the treatment and their organs were 
unharmed by it.
The current drug of choice to treat 
cancer is chemotherapy, which kills the healthy 
cells while trying to kill the cancer cells. With this 
conjugate of malaria protein and toxin, it possible 
to produce a treatment capture and kill only the 
cancer cells in the body.
The biggest questions are, whether 
it’ll work in the human body, and if the human 
body can tolerate the doses needed without 
developing side effects?. Further researches 
in animal models are needed to review the 
pathophysiological pattern of this conjugate 
before human trials can commence.
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